

MOLPHARM/2004/007724

**RGS2 is a mediator of nitric oxide action on blood pressure  
and vasoconstrictor signaling**

**Xiaoguang Sun, Kevin M. Kaltenbronn,  
Thomas H. Steinberg and Kendall J. Blumer**

**Department of Cell Biology and Physiology  
Washington University School of Medicine  
660 S. Euclid Ave.  
St. Louis, MO 63110**

**a)** Running title: RGS2 mediates nitric oxide action

**b)** Corresponding author:

Kendall J. Blumer

Department of Cell Biology and Physiology

Washington University School of Medicine

660 S. Euclid Ave.

St. Louis, MO 63110

[kblumer@cellbio.wustl.edu](mailto:kblumer@cellbio.wustl.edu)

ph. 314-362-1668

fax 314-362-7463

**c)** # text pages: 39; # tables: none; # figures: 6; # references: 44; # words in abstract:

201; # words in introduction: 744; # words in discussion: 1210

**d)** The abbreviations used are: G protein, guanine nucleotide-binding regulatory protein;

GPCR, G protein-coupled receptor; IP<sub>3</sub>, inositol(1,4,5)*tris*phosphate; IRAG, inhibitory

subunit of the inositol(1,4,5)*tris*phosphate receptor; NO, nitric oxide; PKG1, type I

cGMP-dependent protein kinase; RGS protein, regulator of G protein signaling protein;

SERCA, sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup>-ATPase; SNP, sodium nitroprusside.

## ABSTRACT

The nitric oxide (NO)-cGMP pathway regulates vascular tone and blood pressure by mechanisms that are incompletely understood. RGS2, a GTPase-activating protein for Gq $\alpha$  that is critical for blood pressure homeostasis, has been suggested to serve as an effector of the NO-cGMP pathway that promotes vascular relaxation based on studies of aortic rings *in vitro*. To test this hypothesis and its relevance to blood pressure control, we determined whether RGS2 functions as an NO effector in smooth muscle of the resistance vasculature. We report that: 1) the ability of the NO donor Na-nitroprusside to reduce blood pressure is impaired in RGS2<sup>-/-</sup> mice; 2) vasopressin-triggered Ca<sup>2+</sup> transients are augmented in smooth muscle cells from resistance arteries of RGS2<sup>-/-</sup> mice; 3) cGMP analogs fail to inhibit vasopressin-triggered Ca<sup>2+</sup> transients in smooth muscle cells from resistance arteries of RGS2<sup>-/-</sup> mice even though PKG1 $\alpha$  and PKG1 $\beta$  are expressed and activated normally. These results indicated that the NO-cGMP pathway uses RGS2 as a novel downstream effector to promote vascular relaxation by attenuating vasoconstrictor-triggered Ca<sup>2+</sup> signaling in vascular smooth muscle cells. Genetic or epigenetic impairment of this mechanism may contribute to the development of hypertension, and augmenting it pharmacologically may provide a novel means of treating this disease.

## INTRODUCTION

Vascular tone and blood pressure are regulated by the opposing actions of vasoconstrictor and vasodilatory agonists that signal via G protein-coupled receptors (GPCRs<sup>1</sup>) (reviewed in (Carvajal et al., 2000; Lincoln et al., 2001; Munzel et al., 2003)). Vasoconstrictors such as angiotensin II, endothelin, vasopressin and norepinephrine signal via GPCRs coupled to the heterotrimeric G protein Gq. Gq activates signaling cascades in smooth muscle cells that trigger several responses including Ca<sup>2+</sup> release from intracellular stores and Ca<sup>2+</sup> entry across the plasma membrane, resulting in myosin light chain phosphorylation and contraction.

Vasoconstrictor signaling and contraction are potently antagonized by vasodilatory agonists such as acetylcholine, which signal via GPCRs in endothelial cells, producing nitric oxide (NO) and other vasoactive substances that relax smooth muscle cells. NO relaxes smooth muscle by activating guanylyl cyclase, producing cGMP and activating type I cGMP-dependent protein kinases (PKG1, or cGK1). Activated PKG1 exerts its effects in part by blunting vasoconstrictor-triggered Ca<sup>2+</sup> transients (Felbel et al., 1988; Francis et al., 1988; Lincoln et al., 1990; Pfeifer et al., 1998) and impairing Ca<sup>2+</sup> sensitivity of the contractile apparatus (Kitazawa et al., 1991; Lee et al., 1997; Somlyo and Somlyo, 2000). PKG1 attenuates Ca<sup>2+</sup> transients by several mechanisms, including: 1) phosphorylation and activation of IRAG, an inhibitory subunit of the inositol(1,4,5)trisphosphate (IP<sub>3</sub>) receptor (Ammendola et al., 2001; Schlossmann et al., 2000) ; 2) phosphorylation and inactivation of phospholamban (Cornwell et al., 1991;

Raeymaekers et al., 1988), the inhibitory subunit of the sarcoplasmic/endoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase (SERCA) that clears  $\text{Ca}^{2+}$  from the cytoplasm; and 3) phosphorylation and activation of  $\text{BK}_{\text{Ca}}$  channels (Alioua et al., 1998; Fukao et al., 1999), thereby hyperpolarizing the plasma membrane and blunting  $\text{Ca}^{2+}$  entry via L-type channels.

PKG1 also attenuates early events in GPCR-activated  $\text{Ca}^{2+}$  signaling pathways, including GPCR-stimulated phospholipase C activation and  $\text{IP}_3$  accumulation (Azula et al., 1996; Hirata et al., 1990; Lincoln and Cornwell, 1993). Inhibition of these early signaling mechanisms that otherwise are responsible for amplifying GPCR-generated signals may provide a particularly important mechanism by which cGMP attenuates  $\text{Ca}^{2+}$  signaling and promotes relaxation. However, this hypothesis has not been tested. Likewise, the mechanisms by which cGMP inhibits GPCR signaling pathways leading to  $\text{IP}_3$  production are poorly understood (reviewed in (Carvajal et al., 2000)). However, evidence suggests that PKG1 can phosphorylate phospholipase  $\text{C}\beta$  (Xia et al., 2001) and receptors (Wang et al., 1998), potentially uncoupling them from G proteins.

Several observations suggested that RGS2 may function as a novel target or effector of the NO-cGMP pathway that controls blood pressure and vascular tone by regulating vasoconstrictor signaling. RGS2 is one of ~30 RGS proteins (regulator of G protein signaling) that attenuate signaling by stimulating the ability of G protein  $\alpha$  subunits to hydrolyze GTP (reviewed in (Hollinger and Hepler, 2002; Ross and Wilkie, 2000)), returning them to the inactive GDP-bound state. We have shown that RGS2-/-

mice are markedly hypertensive (Heximer et al., 2003). Furthermore, RGS2 binds to and is phosphorylated by PKG1 $\alpha$  *in vitro* and in cells, apparently increasing the ability of RGS2 to associate with membranes and stimulate GTP hydrolysis by Gq $\alpha$  (Tang et al., 2003), the activator of phospholipase C $\beta$  and preferred substrate of RGS2. Aortic rings from RGS2 $^{-/-}$  mice exhibit augmented contraction and impaired cGMP-mediated relaxation *in vitro* (Tang et al., 2003). However, the significance of these *in vitro* studies for blood pressure homeostasis is not clear because the aorta does not have a major role in blood pressure regulation, and impaired NO- or cGMP-mediated relaxation of the aorta was observed only when endothelium was denuded (Tang et al., 2003). Whether RGS2 regulates contraction or relaxation of smooth muscle of the resistance vasculature, which critically determines blood pressure, is an important problem that has not been investigated. Likewise, the vascular smooth muscle signaling mechanisms that are altered in cells lacking RGS2 are poorly understood.

To identify physiologic and cellular signaling mechanisms by which RGS2 regulates blood pressure, we have determined whether this regulatory protein functions in smooth muscle of the resistance vasculature as an effector of the NO-cGMP pathway that promotes relaxation. We have investigated whether RGS2 mediates the ability of an NO donor that acts directly on smooth muscle to reduce blood pressure and the ability of cGMP analogs to attenuate vasoconstrictor-induced Ca<sup>2+</sup> signaling in resistance artery smooth muscle cells *in vitro*. The results provide the first evidence indicating that RGS2 mediates the action of the NO-cGMP pathway on blood pressure by promoting relaxation

MOLPHARM/2004/007724

of the resistance vasculature through its ability to attenuate vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling.

MOLPHARM/2004/007724

## MATERIALS AND METHODS

*Mice and Blood Pressure Measurements*—All procedures using mice were performed in strict accordance with protocols approved by the Washington University School of Medicine Animal Studies Committee. Wild type, RGS<sup>2+/-</sup> and RGS2<sup>-/-</sup> mice backcrossed >10 generations into the C57BL/6 background were used in this study (Heximer et al., 2003; Oliveira-Dos-Santos et al., 2000). Male RGS<sup>2+/+</sup> and <sup>-/-</sup> mice aged 3-5 mo were obtained by crossing RGS<sup>2+/-</sup> mice. For measuring blood pressure, mice were anesthetized with a 1.5% isoflurane/oxygen mixture administered with a vaporizer (Ohmeda Isotec 3). Isoflurane was used because it caused the least depression of heart rate compared to other anesthetics (ketamine/xylazine (87mg/kg and 13.4 mg/kg IP, respectively), urethane (1500mg/kg IP), avertin (250 mg/kg IP) or metofane inhalation (data not shown; see (Lorenz, 2002))). Depth of anesthesia was assessed by lack of response to a pinch. As described in our previous study (Heximer et al., 2003), we recorded heart rate (HR) and mean arterial pressure (MAP) by catheterizing the right common carotid artery with a Millar 1.4 French blood pressure probe and transducer (Millar Instruments Inc., Houston, Texas, USA) coupled to a Powerlab/4sp data acquisition system (ADInstruments, New Castle, NSW, Australia) and passing the probe into the ascending aorta. All vasoactive drugs (Sigma) diluted in 0.9% NaCl were administered intravenously by catheterization of the left jugular vein with polyethylene tubing (PE-10) attached to a 0.5 ml syringe. Drugs were administered continuously via an infusion pump (kdScientific Model 200 Series) as 20 µl doses added continuously at a rate of 2 µl/s or as a bolus dose of 5 µl added over 3-5 s. Saralasin (SAR; 40 µg/kg/min (Ullman, 1999)) was infused intravenously for 10 min to block angiotensin receptors and



MOLPHARM/2004/007724

reduce blood pressures in wild type and RGS2<sup>-/-</sup> mice to similar levels. After equivalent baseline blood pressures were established, we administered to each mouse a series of bolus injections containing phenylephrine (PE; 25 µg/kg IV, which increased MAP to 70% of the value obtained with a maximal dose of PE (Heximer et al., 2003)) alone or in combination with various amounts of Na-nitroprusside (SNP): PE alone; PE+ 15 µg/kg SNP; PE + 45 µg/kg SNP. These are the lowest effective doses of SNP as established previously (Holschneider et al., 2002). After a given injection exerted its effects on blood pressure and blood pressure values returned to starting baseline values, a subsequent injection was administered. After the effects of the last PE+SNP injection waned, we administered a final dose of PE alone (25 µg/kg) and recorded the resultant pressor response. Because this pressor response was indistinguishable in magnitude and kinetics relative to the pressor response elicited by PE at the beginning of the experiment (data not shown), we concluded that the intervening administration of PE+SNP did not damage the resistance vasculature or heart. Whether such damage occurred potentially was a concern because SNP can be metabolized into superoxide or peroxynitrite which, if present long enough, can trigger apoptosis of smooth muscle cells (reviewed by (Yamamoto and Bing, 2000)). SAR (60 µg/kg) was administered between injections as needed to maintain AT1 receptor blockade.

*Cell Culture and Ca<sup>2+</sup> Signaling*—Vascular smooth muscle cells were isolated from thoracic aortas of age-matched (4 mo) wild type and RGS2<sup>-/-</sup> mice as described previously (Heximer et al., 2003). Briefly, freshly isolated aortas were digested with collagenase (0.07%, w/v) and elastase (0.03%, w/v) with gentle agitation for 30min at

MOLPHARM/2004/007724

37°C in DMEM digestion buffer. Dissociated cells were collected by centrifugation and seeded on poly-L-lysine coated coverslips. Cells were grown 3-5d in DMEM/F-12 media containing 20% FCS and 2mM glutamine with penicillin and streptomycin. Smooth muscle cells from mesenteric resistance arteries were isolated and cultured, as described (Dubey and Overbeck, 1994; Rodrigo et al., 2002). Briefly, after mice were euthanized by CO<sub>2</sub> inhalation, a midline incision was made and the mesenteric arcade containing arteries and veins was exposed. Superficial veins and fatty tissue were removed to expose resistance arteries (diameter ~100 μm). Resistance arteries were excised and incubated in DMEM. After remaining fatty tissue and blood clots were removed, arteries were cut into small pieces and placed between one coverslip treated with 0.5% poly-L-lysine and another untreated coverslip in a 24-well plate. Cells were cultured 7-10d in DMEM/F12 containing 20% FBS, 20ng/ml PDGF, 2mM glutamine, penicillin and streptomycin. Staining with anti-smooth muscle α-actin antibody revealed that aortic and mesenteric artery cultures contained >90% smooth muscle cells (data not shown).

For Ca<sup>2+</sup> signaling experiments, vascular smooth muscle cells from aorta or mesenteric resistance arteries were washed and incubated in 4 μM Fura-2/AM (Molecular Probes Inc., Eugene, OR) in Ca<sub>1</sub> solution (11 mM glucose, 130 mM NaCl, 4.8 mM KCl, 1.2 mM MgCl<sub>2</sub>, 17 mM HEPES, 1 mM CaCl<sub>2</sub>, pH 7.3) for 30 min at 37°C. Cells were washed once, and incubated in Ca<sub>1</sub> without Fura-2 for 10 min at 37°C to allow hydrolysis of the acetoxymethyl ester. Coverslips were placed in a RC-26G large open-bath recording chamber (Warner Instrument Corp., Hamden, CT) mounted on a Nikon Eclipse E600 FN microscope equipped with a Nikon Fluor 40X/0.80 water immersion

lens (Nikon Inc., Melville, NY). Excitation light (340 nm/380 nm) was provided by a TiLL Polychrome IV monochromator (TiLL Photonics GmbH, Martinsried, Germany) in conjunction with a 495-nm dichroic mirror and a  $525 \pm 20$ -nm emission filter (Chroma Technology Corp., Brattleboro, VT). To activate PKG1 in VSMCs, cells were mounted in the recording chamber as described above, and treated 10min with 8-Br-cGMP (1mM) or 8-pCPT-cGMP (100 $\mu$ M). During subsequent stimulation with agonists, 8-Br-cGMP (1mM) or 8-pCPT-cGMP (100 $\mu$ M) was also present. Fluorescence ratio imaging was performed with TiLLvisION 4.0 imaging software (TiLL Photonics GmbH), and images were acquired with a SensiCam cooled CCD camera (PCO Computer Optics GmbH, Kelheim, Germany). Regions of interest (ROI) contained 10-20 VSMCs. Image pairs of the ROI were taken every 2s and background-corrected ratio images (340 nm/380 nm) were obtained. Data for each ROI were collected as relative ratio values over time. Ratio data were converted to  $[Ca^{2+}]_i$  by using a standard look-up table created with a  $Ca^{2+}$  calibration kit (Molecular Probes, Eugene, OR).

*Immunoblotting*—Aortas were minced and incubated 30min with or without 8-pCPT-cGMP (100 $\mu$ M) in DMEM/F-12 at 37°C with 95%O<sub>2</sub> / 5%CO<sub>2</sub> and snap frozen in liquid nitrogen. Samples were thawed and homogenized with preheated (95°C) Laemmli sample buffer containing SDS. After extracts were centrifuged the supernatant fractions were collected. Samples (20 $\mu$ g protein/lane) were resolved by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked 1h at room temperature in PBS-0.1% Tween 20 (PBS-T) containing 5% fat-free dried milk and incubated overnight at 4°C with primary antibody (anti-PKG1 $\alpha$  or PKG1 $\beta$  antibodies, Santa Cruz

MOLPHARM/2004/007724

Biotechnology, Santa Cruz, CA, diluted 1:300 in PBS-T+1% milk; anti-VASP, diluted 1:500, or anti VASP monoclonal antibodies specific for phosphoserine-157 or phosphoserine-239, diluted to 0.5 $\mu$ g/ml, Alexis, Inc., San Diego, CA) (Smolenski et al., 1998). Blots were washed and incubated 1h with horseradish peroxidase-conjugated secondary antibodies (ICN, Irvine, CA, diluted 1:3000) followed by enhanced chemiluminescence detection.

*Statistics*—Student's *t* test (two-tailed, two sample, equal variance) was used to determine whether differences in the values of blood pressure or [Ca<sup>2+</sup>] obtained with wild type and RGS2<sup>-/-</sup> mice or cells were statistically significant ( $p < 0.05$ ).

## RESULTS

### *RGS2<sup>-/-</sup> Mice Exhibit Impaired Blood Pressure Response to Na-Nitroprusside—*

To determine whether RGS2 promotes NO-mediated relaxation of smooth muscle in the resistance vasculature, we used the following procedure in which blood pressure recordings were employed to assess contraction and relaxation of the resistance vasculature independent of the endothelium in wild type and RGS2<sup>-/-</sup> mice. To record blood pressure and heart rates, we inserted a pressure-transducing catheter into the right common carotid artery and passed it to the ascending aorta of mice anesthetized with isoflurane (Lorenz, 2002). The left jugular was catheterized with PE10 tubing to administer vasoactive compounds. Because RGS2<sup>-/-</sup> mice exhibit elevated blood pressure that depends nearly entirely on signaling by angiotensin II type I (AT1) receptors, we infused an angiotensin II receptor blocker (saralasin, a weak partial agonist; 40 µg/kg/min IV for 10 min) to produce similar blood pressures in wild type and RGS2<sup>-/-</sup> mice (MAP~70mmHg; Figure 1A). Because saralasin has a half-life of a few minutes, we administered additional doses of this drug as required in subsequent experiments to maintain baseline MAP values.

To verify that mice responded to vasoactive substances under these conditions, we administered a single bolus injection of phenylephrine (PE, 25µg/kg IV), which stimulates contraction of the resistance vasculature by activating Gq-coupled  $\alpha$ 1-adrenergic receptors, and followed changes in blood pressure (mean arterial pressure or MAP) and heart rate (HR). The results shown in Figure 1B indicated that wild type and RGS2<sup>-/-</sup> mice responded similarly to PE challenge. Following PE administration, blood

MOLPHARM/2004/007724

pressure in wild type and RGS2<sup>-/-</sup> mice quickly rose to similar levels and then declined to baseline values within ~2min. As expected for mice with functional baroreflexes, PE infusion caused HR to change inversely with respect to MAP. The similar effects of PE on MAP and HR in wild type and RGS2<sup>-/-</sup> mice are consistent with results of our previous dose-response experiments showing that increases in blood pressure elicited by various doses of PE are not affected by the loss of RGS2 (Heximer et al., 2003). Thus, there was no evidence suggesting that PE-induced contraction of the resistance vasculature was augmented in RGS2<sup>-/-</sup> mice, in contrast to the augmentation of PE-induced contraction of aortic rings from RGS2<sup>-/-</sup> mice observed *in vitro* (Tang et al., 2003).

To determine whether RGS2 mediates the ability of the NO pathway to relax the resistance vasculature and decrease blood pressure, we prepared saralasin-treated mice as described above and then administered a bolus injection of PE (25µg/kg, as before) that contained either of two concentrations (15 or 45µg/kg IV) of the short-lived NO donor Na-nitroprusside (SNP). Controls with wild type mice indicated that SNP attenuated the initial PE-induced pressor response (i.e. maximal rise in MAP was reduced relative to PE-only controls), and then drove blood pressure to levels below starting baseline values (Figure 1C and D). Owing to the short lifetime of SNP in the circulation, these vasodilatory responses were transient as indicated by the return of blood pressure to baseline values within ~90s.

Results obtained from identical experiments performed with RGS2<sup>-/-</sup> mice indicated that SNP-induced vasodilatation was significantly impaired (Figure 1C and D). At either a low or high dose of SNP, the vasodilatory effect observed was reduced in magnitude (i.e. MAP declined less in RGS2<sup>-/-</sup> mice) and duration (i.e. after reaching its low point, MAP in RGS2<sup>-/-</sup> mice returned to baseline values more rapidly). In contrast, during these experiments heart rates were indistinguishable between wild type and RGS2<sup>-/-</sup> mice, thereby ruling out one potential cause for differences in SNP-induced blood pressure responses. The impairment of SNP-triggered blood pressure responses in RGS2<sup>-/-</sup> mice were unlikely to be caused by differences in blood volume regulation because the effects of SNP occurred over short time scales (<2 min) and were rapidly reversible. Therefore, the diminished effects of SNP on blood pressure regulation in RGS2<sup>-/-</sup> mice were indicative of impaired relaxation of the resistance vasculature. However, SNP action was not completely blocked in RGS2<sup>-/-</sup> mice, consistent with the hypothesis that the NO-cGMP pathway uses RGS2 and other targets to promote relaxation.

*Augmented Vasoconstrictor-Induced Ca<sup>2+</sup> Signaling in VSMCs from RGS2*

*Knockout Mice*—The preceding results supported the hypothesis that RGS2 is an important effector of the NO-cGMP pathway in smooth muscle that promotes vascular relaxation. To test this hypothesis directly, we investigated whether RGS2 regulates smooth muscle cell signaling pathways that control contraction or relaxation. This hypothesis has not been examined previously, although studies have shown that overexpression of RGS2 strongly inhibits signaling by various Gq-coupled receptors

(Heximer et al., 1999; Heximer et al., 1997), and overexpression of the domain of RGS2 that binds PKG1 $\alpha$  inhibits the ability of cGMP analogs to attenuate Gq signaling in fibroblasts (Tang et al., 2003). Although the latter result suggested that RGS2 is a target of PKG1, it did not address what occurs in vascular smooth muscle cells or whether RGS2 has a major or minor role mediating the effects of PKG1. These uncertainties remained because overexpression of the PKG1-binding domain of any target protein could block many or all the effects of this protein kinase. Analyzing cells lacking RGS2 provides a clearer means of addressing these questions.

To determine whether RGS2 regulates signaling in vascular smooth muscle cells (VSMCs), we analyzed the ability of various agonists that signal via Gq coupled receptors to trigger Ca<sup>2+</sup> transients in VSMCs from wild type and RGS2<sup>-/-</sup> mice. Experiments were performed with primary VSMCs from both aorta and mesenteric resistance arteries isolated, cultured and loaded with Fura-2 as described in “Materials and Methods”.

First we screened various GPCR agonists for those that elicited robust Ca<sup>2+</sup> transients in the majority of cells. The results of these Ca<sup>2+</sup> imaging experiments performed in the presence of extracellular Ca<sup>2+</sup> indicated that arginine-8-vasopressin (AVP, a vasopressin receptor agonist) and UTP (a P2Y receptor agonist), which signal via receptors coupled to Gq (the preferred substrate of RGS2 (Heximer et al., 1999)), elicited robust increases in intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) in >90% of aortic or mesenteric resistance artery VSMCs (A-VSMCs or MA-VSMCs, respectively; data not



shown). In contrast, phenylephrine or angiotensin II elicited weaker or heterogeneous responses (~30% of cells responded; data not shown), indicating that receptors for these agonists were less well or heterogeneously expressed. Subsequent experiments therefore used A-VSMCs and MA-VSMCs stimulated with AVP, an agonist relevant to blood pressure control, or UTP, in order to determine whether the effects of RGS2 were receptor-specific. Equivalent results were obtained with both agonists (data not shown), consistent with previous studies indicating that, unlike several other RGS proteins, RGS2 does not appear to exhibit receptor-specific regulation of Gq signaling (Wang et al., 2004; Xu et al., 1999). Therefore, only data obtained with AVP are presented below.

Figure 2 shows results indicating that the potency and efficacy of AVP were augmented in A-VSMCs and MA-VSMCs from RGS2<sup>-/-</sup> mice. When stimulated by a maximally effective dose of AVP, A- and MA-VSMCs from RGS2<sup>-/-</sup> mice exhibited peak Ca<sup>2+</sup> transients that were 20-30% higher than obtained with wild type cells (Figure 2A and 2E). By normalizing the data to the maximal peak value, we noted that the Ca<sup>2+</sup> transients were more sustained in A- and MA-VSMCs from RGS2<sup>-/-</sup> mice (Figure 2B and 2F). By measuring peak Ca<sup>2+</sup> responses elicited by various concentrations of AVP, we found that the potencies of these agonists were augmented 2- to 4-fold in A- and MA-VSMCs from RGS2<sup>-/-</sup> mice relative to wild type controls (Figure 2C, D, G and H). These effects were not due to changes in intracellular Ca<sup>2+</sup> pools, because similar Ca<sup>2+</sup> responses were observed with wild type and RGS2<sup>-/-</sup> A- and MA-VSMCs treated with ionomycin in the absence of extracellular Ca<sup>2+</sup> (results presented in next section). Therefore, augmentation of AVP-stimulated Ca<sup>2+</sup> signaling in RGS2<sup>-/-</sup> cells may be

MOLPHARM/2004/007724

caused by more complete release of  $\text{Ca}^{2+}$  from intracellular stores, augmented influx of  $\text{Ca}^{2+}$  from the medium and/or attenuated  $\text{Ca}^{2+}$  re-uptake into ER stores. In contrast to these findings, we previously showed that loss of RGS2 does significantly augment vasoconstrictor-triggered rises in blood pressure (Heximer et al., 2003), possibly because loss of RGS2 does not augment activation of RhoA or other molecules that promote contraction. Although the present study was not designed to address such questions, the results of the  $\text{Ca}^{2+}$  signaling experiments presented above established a system that enabled us to address whether the NO-cGMP pathway uses RGS2 to attenuate vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling.

*RGS2 Mediates the Ability of cGMP Analogs to Attenuate Vasoconstrictor-Induced  $\text{Ca}^{2+}$  Transients*—A principal means by which the NO-cGMP pathway inhibits contraction and causes relaxation is by blunting  $\text{Ca}^{2+}$  transients triggered by vasoconstrictors. RGS2 could be an especially important effector of the NO-cGMP pathway because it is a powerful inhibitor of Gq, the G protein that activates phospholipase C $\beta$  to produce the second messenger inositol 1,4,5-*tris*phosphosphate (IP<sub>3</sub>) responsible for triggering release of  $\text{Ca}^{2+}$  from intracellular stores. RGS2 therefore is poised to regulate the amplification of receptor-generated  $\text{Ca}^{2+}$  signals, possibly by serving as a target or effector of the NO-cGMP pathway.

To determine whether RGS2 mediates the ability of cGMP to attenuate vasoconstrictor-induced  $\text{Ca}^{2+}$  transients, we performed  $\text{Ca}^{2+}$  imaging experiments with wild type and RGS2<sup>-/-</sup> A- and MA-VSMCs that were treated with or without 8-Br-cGMP

(1mM) or 8-pCPT-cGMP (100 $\mu$ M) to activate endogenously expressed cGMP-dependent protein kinases (PKG1) and then stimulated with AVP or UTP. Both cGMP analogs were used to ensure that the effects observed were due to activation of PKG1 rather than inhibition of phosphodiesterase activity that could raise levels of both cGMP and cAMP and thus potentially make it difficult to determine which second messenger system was operative (Butt et al., 1992). Because equivalent results were observed with both cGMP analogs and receptor agonists (data not shown), only the results of experiments using 8-pCPT-cGMP and AVP are presented below.

The results of Ca<sup>2+</sup> imaging experiments revealed a striking difference in the ability of wild type and RGS2<sup>-/-</sup> VSMCs to respond to cGMP analogs. As expected, treatment of wild type A- or MA-VSMCs with 8-pCPT-cGMP significantly attenuated peak Ca<sup>2+</sup> signals elicited by a maximally effective concentration of AVP (Figure 3A). In contrast, treatment of RGS2<sup>-/-</sup> A- or MA-VSMCs with 8-pCPT-cGMP had minimal inhibitory effect on peak AVP-triggered Ca<sup>2+</sup> transients (Figure 3B). This effect was not due to differences in the amount of Ca<sup>2+</sup> in intracellular stores, because ionomycin elicited similar Ca<sup>2+</sup> responses in wild type and RGS2<sup>-/-</sup> cells pretreated or not with 8-pCPT-cGMP in the absence of extracellular Ca<sup>2+</sup> (Figure 4).

To quantify the inhibitory effects cGMP analogs on AVP-triggered Ca<sup>2+</sup> responses in wild type and RGS2<sup>-/-</sup> VSMCs, we calculated the integrated areas under Ca<sup>2+</sup> response curves. Results shown in Figure 4 indicated that in wild type cells 8-pCPT-cGMP attenuated AVP-triggered Ca<sup>2+</sup> responses by >60%. In contrast, in RGS2<sup>-/-</sup>

VSMCs 8-pCPT-cGMP had little inhibitory effect (<5%) on AVP-elicited  $\text{Ca}^{2+}$  responses. The greatly diminished inhibitory effect of 8-pCPT-cGMP in RGS2<sup>-/-</sup> cells was not receptor-specific because similar results were obtained by comparing the integrated UTP-stimulated  $\text{Ca}^{2+}$  signals elicited in wild type and RGS2<sup>-/-</sup> VSMCs treated with or without 8-pCPT-cGMP (data not shown).

Results shown in Figure 4 also indicated that loss of RGS2 greatly augmented the magnitude of integrated  $\text{Ca}^{2+}$  responses elicited either in the absence or presence of 8-pCPT-cGMP. In the absence of 8-pCPT-cGMP, AVP-triggered  $\text{Ca}^{2+}$  responses were 2-fold greater in RGS2<sup>-/-</sup> cells relative to wild type controls. In the presence of 8-pCPT-cGMP, AVP-elicited  $\text{Ca}^{2+}$  responses were 4- to 5-fold greater in RGS2<sup>-/-</sup> VSMCs relative to wild type controls. Loss of RGS2 did not affect intracellular  $\text{Ca}^{2+}$  stores either in the presence or absence of 8-pCPT-cGMP, as indicated by quantifying the integrated  $\text{Ca}^{2+}$  responses elicited by ionomycin in the absence of extracellular  $\text{Ca}^{2+}$ . Therefore, A- or MA-VSMCs lacking RGS2 exhibited profoundly defective cGMP-mediated inhibition of AVP-induced  $\text{Ca}^{2+}$  signaling as well as significantly augmented  $\text{Ca}^{2+}$  transients with or without treatment with cGMP analogs. RGS2 deficiency thereby may impair vascular relaxation at least in part by blocking the inhibitory action of the NO-cGMP pathway on vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling.

*Expression and Activation of PKG1 in VSMCs is Independent of RGS2*—One possible explanation for the results described above was that PKG1 expression or activation is significantly impaired in VSMCs from RGS2<sup>-/-</sup> mice. However, results of

immunoblotting experiments argued against this hypothesis. The levels of PKG1 $\alpha$  and  $\beta$  (the two splice variants expressed in VSMCs) were indistinguishable in wild type and RGS2<sup>-/-</sup> A-VSMCs (Figure 5A; MA-VSMCs could not be obtained in quantities sufficient for immunoblotting experiments). Furthermore, PKG1 activity was stimulated similarly in wild type and RGS2<sup>-/-</sup> A-VSMCs following incubation with the specific activator 8-pCPT-cGMP. This conclusion was drawn from the results of immunoblotting experiments that detected similar levels of endogenously expressed VASP phosphorylated on serine-239 (47kDa band recognized by a monoclonal antibody specific for phosphoserine-239 of VASP), or on serine-239 and serine-157 (50kDa band recognized by monoclonal antibodies specific for phosphoserine-239 or phosphoserine-157 of VASP; both are established *in vivo* PKG1 phosphorylation sites (Aizawa et al., 2003; Smolenski et al., 1998)) in wild type and RGS2<sup>-/-</sup> aortic VSMCs (Figure 5B). Therefore, VSMCs lacking RGS2 did not exhibit detectable impairment of PKG1 expression or activation, suggesting that RGS2 functions downstream of PKG1. Accordingly, when taken together the results presented above indicated that RGS2 is a novel effector of the NO-cGMP signaling pathway that is required to inhibit vasoconstrictor-induced Ca<sup>2+</sup> signaling, promote relaxation of the resistance vasculature and regulate blood pressure.

## DISCUSSION

The results of this investigation indicate that RGS2, a negative regulator of signaling by Gq-coupled receptors, is one of several molecules that mediate the action of NO on blood pressure and vasoconstrictor signaling in smooth muscle cells from the resistance vasculature. Accordingly, they provide new insight into the mechanisms that regulate blood pressure, vascular tone and smooth muscle cell signaling, which may be relevant to the genesis or treatment of hypertension, as discussed below.

The NO-cGMP pathway provides a principal means by which blood pressure and vascular tone are regulated because it employs several mechanisms that inhibit the action of vasoconstrictors. Our findings indicate that one of these mechanisms requires RGS2 because the ability of an NO donor to antagonize the pressor effects of phenylephrine is impaired in RGS2<sup>-/-</sup> mice. RGS2 could mediate the action of the NO-cGMP pathway in several tissues because it is widely expressed, including in vascular smooth muscle and kidney (reviewed in (Kehrl and Sinnarajah, 2002)). However, smooth muscle of the resistance vasculature is likely to be an important locus of RGS2 function because we found that the *acute* action of an NO donor on blood pressure is impaired in RGS2<sup>-/-</sup> mice. Furthermore, the loss of RGS2 in primary smooth muscle cells from mesenteric resistance arteries increases the magnitude and duration of agonist-induced Ca<sup>2+</sup> responses and blocks the ability of cGMP analogs to attenuate agonist-induced Ca<sup>2+</sup> signaling. Because expression and activation of PKG1 $\alpha$  and  $\beta$  are normal in VSMCs from RGS2<sup>-/-</sup> mice, our findings strongly support the hypothesis that RGS2 is an essential downstream effector of the NO-cGMP pathway that regulates blood pressure by

attenuating vasoconstrictor receptor signaling. RGS2 apparently is a direct effector of PKG1 because it can be phosphorylated and activated by this protein kinase (Tang et al., 2003).

How does RGS2 mediate the inhibitory effects of the NO-cGMP pathway on vasoconstrictor-induced  $Ca^{2+}$  signaling? As shown in Figure 6, we propose that RGS2 attenuates signaling by Gq, the G protein coupled to many vasoconstrictor receptors. This hypothesis is supported by studies indicating that RGS2 is a potent GTPase-activating protein that is selective for Gq (Heximer et al., 1999; Heximer et al., 1997; Ingi et al., 1998). Accordingly, loss of RGS2 is hypothesized to increase the lifetime of Gq $\alpha$ -GTP, resulting in greater or abnormally prolonged activation of phospholipase C $\beta$ , production of IP $_3$  and release of  $Ca^{2+}$  from intracellular stores or entry of  $Ca^{2+}$  from the medium. Indeed, augmented agonist-induced IP $_3$  production has been shown to occur RGS2 $^{-/-}$  cells (Wang et al., 2004). Thus, we propose that the NO-cGMP pathway triggered by the action of vasodilatory agonists inhibits vasoconstrictor-induced  $Ca^{2+}$  signaling by activating PKG1, which phosphorylates RGS2, increasing its activity as a GAP for Gq $\alpha$  and promoting its association with the membrane (Tang et al., 2003).

Activation of RGS2 by the NO-cGMP pathway appears to be crucial for inhibiting  $Ca^{2+}$  signaling triggered by Gq-coupled vasoconstrictor receptors. Whereas PKG1 activation strongly attenuates (>60%) vasoconstrictor-induced  $Ca^{2+}$  responses in wild type cells, it has little inhibitory effect (~5%) in RGS2  $^{-/-}$  cells. This profound regulatory deficit is remarkable because several other mechanisms allow PKG1 to

attenuate  $\text{Ca}^{2+}$  signaling, including activation of SERCA via phospholamban phosphorylation and inhibition of  $\text{IP}_3$  receptors by IRAG phosphorylation (Ammendola et al., 2001; Cornwell et al., 1991; Raeymaekers et al., 1988; Schlossmann et al., 2000).

However, the profound regulatory deficit in RGS2<sup>-/-</sup> VSMCs is less surprising when one considers that RGS2 controls an early *amplification step* (i.e. Gq-mediated PLC activation and consequent  $\text{IP}_3$  and DAG production) in vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling pathways. Thus, PKG1-activated regulatory mechanisms controlling  $\text{Ca}^{2+}$  release and entry either are impaired in cultured RGS2<sup>-/-</sup> VSMCs or they lack the capacity to compensate adequately for the abnormally strong or prolonged second messenger signals resulting from augmented activation of Gq in cells lacking RGS2.

Although the loss of RGS2 has similar effects on vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling in VSMCs from aorta and mesenteric resistance arteries, two observations suggest that RGS2 deficiency differentially affects the function of the aorta and resistance vasculature. First, loss of RGS2 appears to augment vasoconstrictor-induced contraction of aortic rings but not the resistance vasculature (Heximer et al., 2003; Tang et al., 2003). Second, RGS2 deficiency impairs NO-mediated relaxation of the resistance vasculature, but not endothelium-intact aortic rings (Tang et al., 2003). Assuming that these differences are not due to the distinct means by which contraction and relaxation of aortic rings and the resistance vasculature have been analyzed, they suggest that RGS2 regulates contraction and relaxation of the aorta vs. resistance arteries in significantly different ways. Whether or how this occurs is not yet clear because the loss of RGS2 has



MOLPHARM/2004/007724

similar effects on vasoconstrictor-induced  $\text{Ca}^{2+}$  signaling in VSMCs from aorta and mesenteric resistance arteries. However, other signaling pathways, such as those using RhoA or Erk, that regulate contraction and relaxation or endothelium-smooth muscle communication could be affected differentially in aorta vs. resistance arteries by RGS2 deficiency.

It is striking that RGS2 deficiency nearly completely impairs the inhibitory action of cGMP analogs on vasoconstrictor-induced  $\text{Ca}^{2+}$  transients in VSMCs from mesenteric resistance arteries, but does not completely block the action of an NO donor on blood pressure. These results support the hypothesis that the NO-cGMP pathway uses several mechanisms to promote vascular relaxation *in vivo*, some of which do not require RGS2. For example, RGS2 may not be required for cGMP-mediated relaxation caused by inhibition of RhoA action because G12/13 (which are not regulated by RGS2) rather than Gq/11 may provide the primary means by which vasoconstrictor receptors activate RhoA (Gohla et al., 2000).

VSMCs express several closely related RGS proteins, including RGS2, RGS3 and RGS5 (Wang et al., 2002), each of which probably has crucial roles regulating GPCR signaling in the vasculature. These RGS proteins probably are at least partially redundant because each can regulate Gq signaling and the loss of a single RGS protein (RGS2) only modestly prolongs the kinetics of  $\text{Ca}^{2+}$  signaling. However, RGS2, RGS3 and RGS5 clearly have non-overlapping functions in smooth muscle cells. Indeed, knockdown studies indicate that RGS3 and RGS5 regulate Gq signaling in a receptor-selective

MOLPHARM/2004/007724

manner (Wang et al., 2002). Furthermore, our results show that RGS2 is required for cGMP-mediated inhibition of vasoconstrictor-triggered  $\text{Ca}^{2+}$  signaling. In the absence of RGS2, RGS3 and RGS5 may be unable to carry out this function because they lack sites equivalent to those in RGS2 (Ser-46 and Ser-64) that are phosphorylated by PKG1 (Tang et al., 2003). Thus, RGS2 appears to be unique among these proteins in its ability to serve as an effector of the NO-cGMP pathway that attenuates Gq-mediated  $\text{Ca}^{2+}$  signaling, providing an important and novel crosstalk mechanism for inhibition of vasoconstrictor signaling by vasodilatory agonists.

In conclusion, results presented herein indicate that RGS2 regulates blood pressure to a significant extent by mediating the ability of the NO pathway to relax the resistance vasculature and attenuate vasoconstrictor signaling in vascular smooth muscle cells. Genetic or epigenetic impairment of RGS2 therefore may contribute to the genesis of hypertension. This hypothesis is supported by a recent study showing that RGS2 mRNA expression is downregulated in the vessel wall in a rat L-NAME model of hypertension (Dupuis et al., 2004). Accordingly, pharmacological agents that upregulate RGS2 expression or activity may augment the action of vasodilatory agonists and provide a novel means of treating hypertension.

MOLPHARM/2004/007724

## **ACKNOWLEDGEMENTS**

We thank members of our laboratory for advice and comments.

## REFERENCES

- Aizawa T, Wei H, Miano JM, Abe J, Berk BC and Yan C (2003) Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. *Circ Res* **93**:406-13.
- Alioua A, Tanaka Y, Wallner M, Hofmann F, Ruth P, Meera P and Toro L (1998) The large conductance, voltage-dependent, and calcium-sensitive K<sup>+</sup> channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo. *J Biol Chem* **273**:32950-6.
- Ammendola A, Geiselhoringer A, Hofmann F and Schlossmann J (2001) Molecular Determinants of the Interaction between the Inositol 1,4,5-Trisphosphate Receptor-associated cGMP Kinase Substrate (IRAG) and cGMP Kinase Ibeta. *J Biol Chem*. **276**:24153-24159.
- Azula FJ, Alzola ES, Conde M, Trueba M, Macarulla JM and Marino A (1996) Thrombin-stimulated phospholipase C activity is inhibited without visible delay by a rapid increase in the cyclic GMP levels induced by sodium nitroprusside. *Mol Pharmacol* **50**:367-79.
- Butt E, Nolte C, Schulz S, Beltman J, Beavo JA, Jastorff B and Walter U (1992) Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP. *Biochem Pharmacol* **43**:2591-600.
- Carvajal JA, Germain AM, Huidobro-Toro JP and Weiner CP (2000) Molecular mechanism of cGMP-mediated smooth muscle relaxation. *J Cell Physiol* **184**:409-20.

- Cornwell TL, Pryzwansky KB, Wyatt TA and Lincoln TM (1991) Regulation of sarcoplasmic reticulum protein phosphorylation by localized cyclic GMP-dependent protein kinase in vascular smooth muscle cells. *Molecular Pharmacology* **40**:923-931.
- Dubey RK and Overbeck HW (1994) Culture of rat mesenteric arteriolar smooth muscle cells: effects of platelet-derived growth factor, angiotensin, and nitric oxide on growth. *Cell Tissue Res* **275**:133-41.
- Dupuis M, Soubrier F, Brocheriou I, Raoux S, Haloui M, Louedec L, Michel JB and Nadaud S (2004) Profiling of Aortic Smooth Muscle Cell Gene Expression in Response to Chronic Inhibition of Nitric Oxide Synthase in Rats. *Circulation*.
- Felbel J, Trockur B, Ecker T, Landgraf W and Hofmann F (1988) Regulation of cytosolic calcium by cAMP and cGMP in freshly isolated smooth muscle cells from bovine trachea. *J. Biol. Chem.* **263**:16764-16771.
- Francis S, Noblett B, Todd B, Wells J and Corbin J (1988) Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. *Mol Pharmacol* **34**:506-517.
- Fukao M, Mason HS, Britton FC, Kenyon JL, Horowitz B and Keef KD (1999) Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072. *J Biol Chem* **274**:10927-35.
- Gohla A, Schultz G and Offermanns S (2000) Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. *Circ Res* **87**:221-7.

- Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP and Blumer KJ (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. *J Clin Invest* **111**:445-52.
- Heximer SP, Srinivasa SP, Bernstein LS, Bernard JL, Linder ME, Hepler JR and Blumer KJ (1999) G protein selectivity is a determinant of RGS2 function. *J Biol Chem* **274**:34253-9.
- Heximer SP, Watson N, Linder ME, Blumer KJ and Hepler JR (1997) RGS2/G0S8 is a selective inhibitor of Gqalpha function. *Proc Natl Acad Sci U S A* **94**:14389-93.
- Hirata M, Kohse KP, Chang CH, Ikebe T and Murad F (1990) Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. *J Biol Chem* **265**:1268-73.
- Hollinger S and Hepler JR (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. *Pharmacol Rev* **54**:527-59.
- Holschneider DP, Scremin OU, Roos KP, Chialvo DR, Chen K and Shih JC (2002) Increased baroreceptor response in mice deficient in monoamine oxidase A and B. *Am J Physiol Heart Circ Physiol* **282**:H964-72.
- Ingi T, Krumins AM, Chidiac P, Brothers GM, Chung S, Snow BE, Barnes CA, Lanahan AA, Siderovski DP, Ross EM, Gilman AG and Worley PF (1998) Dynamic regulation of RGS2 suggests a novel mechanism in G-protein signaling and neuronal plasticity. *J Neurosci* **18**:7178-88.
- Kehrl JH and Sinnarajah S (2002) RGS2: a multifunctional regulator of G-protein signaling. *Int J Biochem Cell Biol* **34**:432-8.

- Kitazawa T, Masuo M and Somlyo A (1991) G Protein-Mediated Inhibition of Myosin Light-Chain Phosphatase in Vascular Smooth Muscle. *PNAS* **88**:9307-9310.
- Lee MR, Li L and Kitazawa T (1997) Cyclic GMP Causes Ca<sup>2+</sup> Desensitization in Vascular Smooth Muscle by Activating the Myosin Light Chain Phosphatase. *J. Biol. Chem.* **272**:5063-5068.
- Lincoln TM and Cornwell TL (1993) Intracellular cyclic GMP receptor proteins. *Faseb J* **7**:328-38.
- Lincoln TM, Cornwell TL and Taylor AE (1990) cGMP-dependent protein kinase mediates the reduction of Ca<sup>2+</sup> by cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol* **258**:C399-407.
- Lincoln TM, Dey N and Sellak H (2001) Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. *J Appl Physiol* **91**:1421-30.
- Lorenz JN (2002) A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. *Am J Physiol Regul Integr Comp Physiol* **282**:R1565-82.
- Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F and Walter U (2003) Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3',5'-cyclic monophosphate-dependent protein kinase. *Circulation* **108**:2172-83.
- Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ, Mariathasan S, Sasaki T, Wakeham A, Ohashi PS, Roder JC, Barnes CA, Siderovski DP and Penninger JM (2000) Regulation of T cell activation, anxiety, and male aggression by RGS2. *Proc Natl Acad Sci U S A* **97**:12272-7.

- Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C, Wang G-X, Korth M, Aszodi A, Andersson K-E, Krombach F, Mayerhofer A, Ruth P, Fassler R and Hofmann F (1998) Defective smooth muscle regulation in cGMP kinase I-deficient mice. *EMBO J.* **17**:3045-3051.
- Raeymaekers L, Hofmann F and Casteels R (1988) Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle. *The Biochemical Journal* **252**:269-273.
- Rodrigo MC, Martin DS, Redetzke RA and Eyster KM (2002) A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNAlater. *J Pharmacol Toxicol Methods* **47**:87-92.
- Ross EM and Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. *Annu Rev Biochem* **69**:795-827.
- Schlossmann J, Ammendola A, Ashman K, Zong X, Huber A, Neubauer G, Wang GX, Allescher HD, Korth M, Wilm M, Hofmann F and Ruth P (2000) Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase I $\beta$ . *Nature* **404**:197-201.
- Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H and Walter U (1998) Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. *J Biol Chem* **273**:20029-35.



- Somlyo AP and Somlyo AV (2000) Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. *J Physiol (Lond)* **522**:177-185.
- Tang M, Wang G, Lu P, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y and Mendelsohn ME (2003) Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. *Nat Med* **9**:1506-12.
- Ullman J (1999) Vasopressin and angiotensin II in blood pressure control during isoflurane anesthesia in rats. *Acta Anaesthesiol Scand* **43**:860-5.
- Wang GR, Zhu Y, Halushka PV, Lincoln TM and Mendelsohn ME (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. *Proc Natl Acad Sci U S A* **95**:4888-93.
- Wang Q, Liu M, Mullah B, Siderovski DP and Neubig RR (2002) Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells. *J Biol Chem* **277**:24949-58.
- Wang X, Huang G, Luo X, Penninger JM and Muallem S (2004) Role of RGS2 in Ca<sup>2+</sup> oscillations and adaptation of Ca<sup>2+</sup> signaling to reduce excitability of RGS2<sup>-/-</sup> cells. *J Biol Chem*.
- Xia C, Bao Z, Yue C, Sanborn BM and Liu M (2001) Phosphorylation and regulation of G-protein-activated phospholipase C-beta 3 by cGMP-dependent protein kinases. *J Biol Chem* **276**:19770-7.

MOLPHARM/2004/007724

Xu X, Zeng W, Popov S, Berman DM, Davignon I, Yu K, Yowe D, Offermanns S,

Muallem S and Wilkie TM (1999) RGS proteins determine signaling specificity  
of Gq-coupled receptors. *J Biol Chem* **274**:3549-56.

Yamamoto T and Bing RJ (2000) Nitric oxide donors. *Proc Soc Exp Biol Med* **225**:200-6.

MOLPHARM/2004/007724

### FOOTNOTES

**a)** This work was supported by grants from the NIH (to K.J.B. and T.H.S.) and the Pfizer-Washington University Biomedical Research Agreement (to K.J.B.).

**b)** Reprint requests and correspondence should be addressed to:

Kendall J. Blumer, Ph.D.

Department of Cell Biology and Physiology

Washington University School of Medicine

660 S. Euclid Ave.

St. Louis, MO 63110

## FIGURE LEGENDS

**Figure 1. RGS2 mediates the ability of an NO donor to reduce blood pressure.** The ability the NO donor Na-nitroprusside (SNP) to antagonize the pressor effects the  $\alpha$ 1-adrenergic receptor agonist phenylephrine (PE) was used to assess relaxation of the resistance vasculature in wild type and RGS2<sup>-/-</sup> mice (n=7 wild type; n=8 RGS2<sup>-/-</sup>; s.e.m. indicated by error bars). **A.** Reversal of the hypertensive phenotype of RGS2<sup>-/-</sup> mice upon infusion of the angiotensin II type 1 (AT1) receptor blocker saralasin (40 $\mu$ g/kg/s IV). Saralasin treatment resulted in equivalent baseline blood pressures and heart rates in wild type and RGS2<sup>-/-</sup> mice. The series of data points significantly ( $p < 0.05$ ) different between wild type and RGS2<sup>-/-</sup> mice is marked with an \* over a line. **B.** Blood pressure and heart rate responses of saralasin-treated mice following a single injection of the  $\alpha$ 1-adrenergic agonist phenylephrine (PE; 25  $\mu$ g/kg IV). PE administered at the indicated time point elicited equivalent blood pressure and heart rate responses in wild type and RGS2<sup>-/-</sup> that were indicative of a functional resistance vasculature and baroreflex. **C, D.** Blood pressure and heart rate responses of saralasin-treated mice following injection of PE (25 $\mu$ g/kg IV) containing a low (15 $\mu$ g/kg IV) or high (45 $\mu$ g/kg IV) dose of SNP. Blood pressure responses elicited by SNP were significantly impaired ( $p < 0.05$  as indicated by data points marked with a line and \*\*) in RGS2<sup>-/-</sup> mice, whereas the effect of SNP on heart rate was not significantly different between wild type and RGS2<sup>-/-</sup> mice.

**Figure 2. RGS2 regulates signaling by Gq-coupled vasopressin receptors in aortic and mesenteric resistance artery vascular smooth muscle cells.** Increases in

MOLPHARM/2004/007724

cytoplasmic  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) elicited by the vasopressin receptor agonist arginine-8-vasopressin (AVP) were recorded in Fura-2-loaded primary smooth muscle cells from aorta (A-VSMCs) or mesenteric resistance arteries (MA-VSMCs) from wild type and RGS2<sup>-/-</sup> mice. Results from experiments using AVP were obtained in the continued presence of extracellular  $\text{Ca}^{2+}$ . Fura-2 fluorescence data recorded continuously before and after stimulation were converted to  $[\text{Ca}^{2+}]_i$  with the use of lookup tables generated with a  $[\text{Ca}^{2+}]$  calibration kit. **A, B, E** and **F** show average (n=3-5) time courses of wild type and RGS2<sup>-/-</sup> cells (10-20 cells/field/experiment) stimulated with AVP (100nM). **C, D, G** and **H** show the magnitude of peak  $\text{Ca}^{2+}$  responses of wild type and RGS2<sup>-/-</sup> cells stimulated by various concentrations of AVP. Results of dose-response experiments are the average of 3-5 independent experiments; error bars indicate s.e.m. Statistically significant ( $p < 0.01$ ) differences in the dose-response curves obtained with wild type and RGS2<sup>-/-</sup> cells are indicated by \*.


**Figure 3. RGS2 mediates the ability of cGMP analogs to attenuate signaling by vasopressin receptors in vascular smooth muscle cells.** Increases  $[\text{Ca}^{2+}]_i$  elicited by AVP were recorded in Fura-2-loaded primary smooth muscle cells from aorta (**A**; A-VSMCs) and mesenteric resistance arteries (**B**; MA-VSMCs) from wild type and RGS2<sup>-/-</sup> mice as described in Figure 2. Cells were treated 10min without or with 8-pCPT-cGMP (100 $\mu$ M) prior to stimulation with AVP (100nM) at the indicated time. Time courses shown are the average of 5 independent experiments.

**Figure 4. Quantification of the inhibitory effects of cGMP analogs on vasopressin receptor-mediated  $\text{Ca}^{2+}$  signaling in vascular smooth muscle cells from wild type and RGS2<sup>-/-</sup> mice.** Experiments were conducted as described in Figure 3. The magnitudes of  $\text{Ca}^{2+}$  responses were quantified by integrating areas under time-course curves obtained after stimulating control or 8-pCPT-cGMP-treated cells with AVP (100nM) or ionomycin (1 $\mu$ M). Results shown are the average of 5 independent experiments; s.e.m. is indicated. The inhibitory effect of 8-pCPT-cGMP on AVP-induced  $\text{Ca}^{2+}$  responses in wild type cells was statistically significant ( $p < 0.001$ , indicated by \*). The inhibitory effect of 8-pCPT-cGMP on AVP-induced  $\text{Ca}^{2+}$  responses in RGS2<sup>-/-</sup> cells was not statistically significant. The inhibitory effect of 8-pCPT-cGMP on intracellular  $\text{Ca}^{2+}$  pools released by ionomycin in the absence of extracellular  $\text{Ca}^{2+}$  was not statistically significant.


**Figure 5. Expression and activation of PKG1 in vascular smooth muscle cells from wild type and RGS2<sup>-/-</sup> mice.** Primary aortic vascular smooth muscle cells isolated from wild type and RGS2<sup>-/-</sup> mice were treated 30 min with or without 8-pCPT-cGMP (100 $\mu$ M) and analyzed by immunoblotting with antibodies specific for PKG1 $\alpha$  and PKG1 $\beta$  (**A**) or with antibodies specific for vasodilator-stimulated phosphoprotein (VASP), or VASP specifically phosphorylated on serine-157 or serine-239 (**B**), which are established PKG phosphorylation sites.





MOLPHARM/2004/007724

**Figure 6. Model of RGS2 action as an effector of the NO-cGMP pathway that relaxes the vasculature by attenuating vasoconstrictor signaling.** Details are presented in the text.


**Figure 1**







**Figure 3****A****B**

# Figure 4





**Figure 6**

